Devicare has signed a participative loan worth €2 million from the Innova Global line by Avançsa, assigned to the Business and Expertise Department, with the option to convert the investment into Series A stock in the mid-term.

With this new economic injection, Devicare will continue the strategic development plan of new medical solutions under the Remote Patient Monitoring concept, which simply and economically places patients at the centre of their own healthcare management, known as patient empowerment, as well as the corresponding clinical studies and trials for the expansion throughout the European and North American markets. Currently, the company has ...


Cebiotex, a CataloniaBio member, has launched a new crowdequity campaign to raise €650,000 through CapitalCell in order to ensure its first drug, CEB-01 for post-op treatment of soft-tissue sarcomas, reaches paediatric oncology.

The campaign is part of a €1.6-million round of funding. The biotech firm hopes this capital will be covered with public and private funds, allowing it to begin phase I/II clinical trials on candidate CEB-01 with 15 patients in 2018, and begin proof-of concept testing for new oncology treatments for pancreatic cancer, liver cancer and brain tumours. “The first licences are expected from 2021, with ...


Genesis Biomed, a CataloniaBio member, was presented yesterday Genesis Ventures, a new investment fund located in Barcelona 


Vytrus Biotech, a CataloniaBio member, has raised more than €600,000 in a capital increase it closed on 29 October. This investment came through a crowdequity campaign on the Capital Cell platform.

Specifically, the biotechnology firm raised 110% of its initial goal of €550,000 and has become one of the first companies in Spain to raise over half a million euros through this type of campaign.

The investment will go towards boosting the company’s industrial growth and research lines, as well as helping prepare the company to go public next year.

Vytrus has distribution deals in more than ...


Catalan biomedical companies were able to attract €153.1 million in investment in 2016, a record figure for the sector. This is the main takeaway from the first Study on investment in the Biomedical industry in Catalonia 2017: Achievements and future challenges presented today by CataloniaBio and EY at the Cercle d'Economia in Barcelona before some seventy members of the association, entrepreneurs, investors and other professionals. The study, compiled with an ad-hoc methodology developed by EY, aims to paint an accurate picture of the investment landscape in Catalonia in order to measure and compare it in the coming years ...